2017 White Paper on Recent Issues in Bioanalysis: A Global Perspective on Immunogenicity Guidelines & Biomarker Assay Performance (Part 3 – Lba: Immunogenicity, Biomarkers and PK Assays)

References

• Savoie N , BoothBP, BradleyTet al. 2008 White Paper: the 2nd Calibration and Validation Group Workshop on recent issues in good laboratory practice bioanalysis. Bioanalysis1 (1), 19–30 (2009).
   PubMed Web of Science ®Google Scholar
• Savoie N , GarofoloF, van AmsterdamPet al. 2009 White Paper on recent issues in regulated bioanalysis from the 3rd Calibration and Validation Group Workshop. Bioanalysis2 (1), 53–68 (2010).
   PubMed Web of Science ®Google Scholar
• Savoie N , GarofoloF, van AmsterdamPet al. 2010 White Paper on recent issues in regulated bioanalysis and global harmonization of bioanalytical guidance. Bioanalysis2 (12), 1945–1960 (2010).
   PubMed Web of Science ®Google Scholar
• Garofolo F , RocciM, DumontIet al. 2011 White Paper on recent issues in bioanalysis and regulatory findings from audits and inspections. Bioanalysis3 (18), 2081–2096 (2011).
   PubMed Web of Science ®Google Scholar
• DeSilva B , GarofoloF, RocciMet al. 2012 White Paper on recent issues in bioanalysis and alignment of multiple guidelines. Bioanalysis4 (18), 2213–2226 (2012).
   PubMed Web of Science ®Google Scholar
• Stevenson L , RocciM, GarofoloFet al. 2013 White Paper on recent issues in bioanalysis: “Hybrid” - the best of LBA & LC/MS. Bioanalysis5 (23), 2903–2918 (2013).
   PubMed Web of Science ®Google Scholar
• Fluhler E , HayesR, GarofoloFet al. 2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 1 – small molecules by LCMS). Bioanalysis6 (22), 3039–3049 (2014).
   PubMed Web of Science ®Google Scholar
• Dufield D , NeubertH, GarofoloFet al. 2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 2 – hybrid LBA/LCMS, ELN & regulatory agencies’ input). Bioanalysis6 (23), 3237–3249 (2014).
   PubMed Web of Science ®Google Scholar
• Stevenson L , AmaravadiL, MylerHet al. 2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 3 – LBA and immunogenicity). Bioanalysis6 (24), 3355–3368 (2014).
   PubMed Web of Science ®Google Scholar
• Welink J , FluhlerE, HughesNet al. 2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 1 – small molecules by LCMS). Bioanalysis7 (22), 2913–2925 (2015).
   PubMed Web of Science ®Google Scholar
• Ackermann B , NeubertH, HughesNet al. 2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 2 – hybrid LBA/LCMS and input from regulatory agencies). Bioanalysis7 (23), 3019–3034 (2015).
   PubMed Web of Science ®Google Scholar
• Amaravadi L , SongA, MylerHet al. 2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 3 – LBA, biomarkers and immunogenicity). Bioanalysis7 (24), 3107–3124 (2015).
   PubMed Web of Science ®Google Scholar
• Yang E , WelinkJ, CapeSet al. 2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV) (Part 1 – small molecules, peptides and small molecule biomarkers by LCMS). Bioanalysis8 (22), 2363–2378 (2016).
   PubMed Web of Science ®Google Scholar
• Song A , LeeA, GarofoloFet al. 2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 2 – Hybrid LBA/LCMS and input from regulatory agencies). Bioanalysis8 (23), 2457–2474 (2016).
   PubMed Web of Science ®Google Scholar
• Richards S , AmaravadiL, PillutlaRet al. 2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 3 – LBA, biomarkers and immunogenicity). Bioanalysis8 (23), 2475–2496 (2016).
   PubMed Web of Science ®Google Scholar
• Staack RF , JordanG, HeinrichJ. Mathematical simulations for bioanalytical assay development: the (un-)necessity and (im-)possibility of free drug quantification. Bioanalysis4 (4), 381–395 (2012).
   PubMed Web of Science ®Google Scholar
• Schick E , StaackRF, HaakMet al. Validation of a ligand-binding assay for active protein drug quantification following the ‘free analyte QC concept’. Bioanalysis8 (24), 2537–2549 (2016).
   PubMed Web of Science ®Google Scholar
• Lowes S , AckermannBL. Conference report - AAPS and US FDA Crystal City VI workshop on bioanalytical method validation for biomarkers. Bioanalysis8 (3), 163–167 (2016).
   PubMed Web of Science ®Google Scholar
• Arnold ME , BoothB, KingL, RayC. Workshop report: Crystal City VI-bioanalytical method validation for biomarkers. AAPS J. 18 (6), 1366–1372 (2016).
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research, Center for Veterinary Medicine . Draft guidance for industry, bioanalytical method validation. Rockville, MD, USA (2013). http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm368107.pdf.
   Google Scholar
• Pharmaceutical Research and Manufacturers of America . 2016 Biopharmaceutical research industry profile. PhRMA, Washington DC, USA (April 2016).
   Google Scholar
• DiMasi JA , GrabowskiHG, HansenRW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ. 47, 20–33 (2016).
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) . Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. London, UK (2007). EMEA/CHMP/BMWP/14327/2006. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003946.pdf.
   Google Scholar
• European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) . Draft guideline on Immunogenicity assessment of biotechnology-derived therapeutic proteins. London, UK (2015). EMEA/CHMP/BMWP/14327/2006 Rev. 1. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/10/WC500194507.pdf.
   Google Scholar
• US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health (CDRH) . Draft guidance for industry, assay development and validation for immunogenicity testing of therapeutic protein products. Rockville, MD, USA (2016). http://www.fda.gov/downloads/Drugs/…/Guidances/UCM192750.pdf.
   Google Scholar
• European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) . Guideline on Immunogenicity Assessment of Therapeutic Proteins. London, UK, EMEA/CHMP/BMWP/14327/2006 Rev. 1 (2017). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2017/06/WC500228861.pdf.
   Google Scholar
• European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) . Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. London, UK (2012). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128688.pdf.
   Google Scholar
• Koren E , SmithHW, ShoresEet al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immuno. Met. 333, 1–9 (2008).
   PubMed Web of Science ®Google Scholar
• Wu B , ChungS, JiangXRet al. Strategies to determine assay format for the assessment of neutralizing antibody responses to biotherapeutics. AAPS J. doi: 10.1208/s12248-016-9954-6 (2016) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Shankar G , ArkinS, CoceaLet al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides—harmonized terminology and tactical recommendations. AAPS J. 16 (4), 658–673 (2014).
   PubMed Web of Science ®Google Scholar
• Plotkin SA . Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17 (7), 1055–65 (2010).
   PubMed Web of Science ®Google Scholar
• Zhou L , HoofringSA, WuYet al. Stratification of antibody-positive subjects by antibody level reveals an impact of immunogenicity on pharmacokinetics. AAPS J. 15 (1), 30–40 (2013).
   PubMed Web of Science ®Google Scholar
• Zoghbi J , XuY, GrabertRet al. A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays. J. Immuno. Meth. 426, 62–69 (2015).
   PubMed Web of Science ®Google Scholar
• Wessels U , SchickE, RitterMet al. Novel drug and soluble target tolerant antidrug antibody assay for therapeutic antibodies bearing the P329G mutation. Bioanalysis9 (11), 849–859 (2017).
   PubMed Web of Science ®Google Scholar
• Stubenrauch K , WesselsU, EssigUet al. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies. J. Pharm. Biomed. Anal. 52 (2), 249–254 (2010).
   PubMed Web of Science ®Google Scholar
• Dai S , SchantzA, Clements-EganAet al. Development of a method that eliminates false-positive results due to nerve growth factor interference in the assessment of fulranumab immunogenicity. AAPS J. 16, 464–477 (2014).
   PubMed Web of Science ®Google Scholar
• Gorovits B , WakshullE, PillutlaRet al. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics. J. Immunol. Methods408, 1–12 (2014).
   PubMed Web of Science ®Google Scholar
• Myler H , HruskaMW, SrinivasanSet al. Anti-PEG antibody bioanalysis: a clinical case study with PEG-IFN-λ-1a and PEG-IFN-α2a in naive patients. Bioanalysis7 (9), 1093–1106 (2015).
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) . Guideline on bioanalytical method validation. EMEA/CHMP/EWP/192217/2009. London, UK (2011). www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf.
   Google Scholar
• Bendtzen K , GeborekP, SvensonMet al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 54 (12), 3782–3789 (2006).
   PubMed Web of Science ®Google Scholar
• Jensen PEH , SellebjergF, SondergaardHBet al. Correlation between anti-interferon-b binding and neutralizing antibodies in interferon-b-treated multiple sclerosis patients. Eur. J. Neurol. 19, 1311–1317 (2012).
   PubMed Web of Science ®Google Scholar
• Verch T , RoselleC, Shank-RetzlaffM. Reduction of dilution error in ELISAs using an internal standard. Bioanalysis8 (14), 1451–1464 (2016).
   PubMed Web of Science ®Google Scholar
• Mingozzi F , MausMV, HuiDJet al. CD8+ T-cell responses to adeno associated virus capsid in humans. Nat. Med. 13 (4), 419–422 (2007).
   PubMed Web of Science ®Google Scholar
• Mendell JR , CampbellK, Rodino-KlapacLet al. Dystrophin immunity in Duchenne’s muscular dystrophy. N. Engl J. Med. 363 (15), 1429–1437 (2010).
   PubMed Web of Science ®Google Scholar
• Mingozzi F , HighKA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood122 (1), 23–36 (2013).
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research . Guidance for industry, nonclinical safety evaluation of drug or biologic combinations. Rockville, MD, USA (2006). https://www.fda.gov/OHRMS/DOCKETS/98fr/05d-0004-gdl0002.pdf.
   Google Scholar
• US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research . Guidance for industry, codevelopment of two or more new investigational drugs for use in combination. Rockville, MD, USA (2013). https://www.fda.gov/downloads/drugs/guidances/ucm236669.pdf.
   Google Scholar
• Mobley A , LinderSK, BraeuerRet al. A survey on data reproducibility in cancer research provides insights into our limited ability to translate findings from the laboratory to the clinic. PLoS ONE8 (5), e63221 (2013).
   PubMed Web of Science ®Google Scholar
• Dakappagari N , ZhangH, StephenLet al. Recommendations for clinical biomarker specimen preservation and stability assessments. Bioanalysis9 (8), 643–653 (2017).
   PubMed Web of Science ®Google Scholar
• Ellervik C , VaughtJ. Preanalytical variables affecting the integrity of human biospecimans in biobanking. Clin. Chem. 61 (7), 914–934 (2015).
   PubMed Web of Science ®Google Scholar
• Lee JW , DevanarayanV, BarrettYCet al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 23 (2), 312–328 (2006).
   PubMed Web of Science ®Google Scholar
• Cummings J , WardTH, DiveC. Fit-for-purpose biomarker method validation in anticancer drug development. Drug Discovery Today15 (19–20), 816–825 (2010).
   PubMed Web of Science ®Google Scholar
• Cowan K , GaoX, ParabVet al. Fit-for-purpose biomarker immunoassay qualification and validation: three case studies. Bioanalysis8 (22), 2329–2340 (2016).
   PubMed Web of Science ®Google Scholar
• Hougton R , GoutyD, AllinsonJet al. Recommendations on biomarker bioanalytical method validation by GCC. Bioanalysis4 (20), 2439–2446 (2012).
   PubMed Web of Science ®Google Scholar
• FDA-NIH Biomarker Working Group . BEST (Biomarkers, EndpointS, and other Tools) Resource. US Food and Drug Administration, Silver Spring, MD, USA ; US National Institutes of Health, Bethesda, MD, USA (2016).
   Google Scholar
• Piccoli SP , SauerJM, AmurSet al. Points to consider document: scientific and regulatory considerations for the analytical validation of assays used in the qualification of biomarkers in biological matrices. Biomarker Assay Collaborative Evidentiary Considerations Writing Group. https://healthpolicy.duke.edu/sites/default/files/atoms/files/white_paper_6_14_17_0.pdf.
   Google Scholar
• Ricós C , AlvarezV, CavaF. Current databases on biological variation: pros, cons and progress. Scand. J. Clin. Lab. Invest. 59 (7), 491–500 (1999).
   PubMed Web of Science ®Google Scholar